Timeline
Last
$99.02
+0.27 (0.27%)
24HR+0.3%
1W-4.0%
1M-11.2%
1Y-11.0%
Valuation
- Market Cap
- $21.5B
- Enterprise Value
- $21B
- P/E (TTM)
- —
- Forward P/E
- 793.68x
- Price / Sales
- 26.19x
- EV / EBITDA
- -22.11x
Cash Flow
- Operating Cash Flow
- -$895.7M
- Free Cash Flow
- -$606.2M
- FCF Margin
- -74.0%
- Cash Conversion
- 67.7%
- Cash / Share
- $5.6
Margins & Growth
- Gross Margin
- 81.8%
- Operating Margin
- -65.5%
- EBITDA Margin
- -115.8%
- Net Margin
- -144.4%
- Revenue Growth
- 229.6%
- Earnings Growth
- —
Balance Sheet
- Total Cash
- $1.2B
- Total Debt
- $742.5M
- Net Cash
- $481.1M
- Debt / Equity
- 1.05x
- Current Ratio
- 4.47x
- Quick Ratio
- 3.88x
Returns & Ownership
- Return on Assets
- -31.1%
- Return on Equity
- -294.5%
- Dividend Yield
- —
- Payout Ratio
- 0.0%
- Beta
- 0.79
- Institutional Ownership
- 106.1%
Latest EPS-$0.76+0.2% surprise
Beat rate25%1 print streak
Avg surprise-0.2%vs consensus
Next printAug 6, 2026EPS -$0.68
Quarterly EPS vs consensus
4 quarters Actual ConsensusLabels: beat $ · YoY %Revisions 12 up / 5 down
Earnings transcripts
Read management commentary and analyst Q&A.
No transcript dates are available yet for this ticker.
Forward estimates
Consensus expectations and estimate momentum.
PeriodEPSRevenueGrowth
0QJun 2026
-$0.68$393.4M+59.9%+1QSep 2026
-$0.60$467.1M+65.5%0YDec 2026
-$2.63$1.7B+59.0%+1YDec 2027
$0.12$2.8B+104.7%Primary research
Recent company filings
Jump directly to earnings releases, quarterly reports, and material updates.
8-KCorporate Changes & Voting Matters2026-07-168-KCorporate Changes & Voting Matters2026-05-078-KCorporate Changes & Voting Matters2026-04-078-KCorporate Changes & Voting Matters2026-03-238-KCorporate Changes & Voting Matters2026-02-198-KCorporate Changes & Voting Matters2026-01-098-KCorporate Changes & Voting Matters2025-12-178-KCorporate Changes & Voting Matters2025-11-188-KCorporate Changes & Voting Matters2025-10-308-KCorporate Changes & Voting Matters2025-08-128-KCorporate Changes & Voting Matters2025-08-078-KCorporate Changes & Voting Matters2025-06-13
INSM stock research · Insmed Incorporated
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regim…
| Last price | $99 |
|---|---|
| Day change | +0.27 (0.27%) |
| Market cap | $21.5B |
| P/E (TTM) | — |
| Sector | Healthcare |
| Industry | Biotechnology |